Confidential briefing · Prepared for Ian Partington
War-gaming the process — and the decision in front of us.
Three anchors, all of which survive on their own merits.
Para 2.1(a) on delegation to a Management Vendor; Para 2.1(a) on operation consistent with the Business Plan; Para 2.5(a) on quarterly Platform Revenues reporting; Para 2.5(d) on semi-annual board engagement; Cl 21.9 on the FY24 good-faith assessment.
Williams not being in Schedule 1, and Ian being named in the Business Plan as CEO with salary to Dec 2027, makes the central 2.1(a) breach hard to argue away.
Sch 3 § 1.11 binds the Expert: cannot determine below Nucleus's £2,554,936 floor. Combined with the £1,250,638 withholding release Nucleus has already conceded → ~£3.8m structurally certain.
Dispute is over the increment above floor — Vendors cannot lose in absolute terms.
Foster Denovo: 13bps → 8bps on ~£1.5bn AUA. Lowes: signed pre-removal, contractual terms agreed. Amber River: in active discussion at departure. Kingswood: "very large advisor piece" pending.
The Adviser-segment 188% growth assumption is identifiable as the underperforming line in FY25 actuals.
The CASS Indemnified Conduct write-down to zero in the FY25 Statement shows Nucleus revising its position when challenged. Pattern matches what we'd expect them to do again during a dispute — or in early settlement.
Tetrao silent supporter; Roger Foster active via Stuart; Ian commercially supportive via WealthVector; Management Vendors broadly conflicted but not opposed. The coalition holds, but doesn't run itself — active coordination needed across all parties, particularly around § 9 disclosure and any common-interest privilege wrap.
Not a letter, not a phone call, not a quick adjudication. The Expert is an ICAEW-appointed chartered accountant applying CPR Part 35 evidential standards by convention. The case is built — and lost — on the quality of the documentary record.
Practitioner standards: Kendall on Expert Determination (Sweet & Maxwell); ICAEW Forensic and Expert Witness guidance; Academy of Experts ethics code; CPR Part 35 by convention. Leading authorities: Jones v Sherwood (manifest error), Veba Oil v Petrotrade (scope), Premier Telecom v Webb (review).
Slaughter and May on the other side. Top-three London firm, no real cost ceiling, established procedural-aggression posture. Their playbook isn't to win the substantive case — it's to make winning unaffordable for us.
The Expert is likely to direct us to fill any gaps once appointed. The professional question is not whether to produce these documents but how thoroughly.
OC partner-led drafting; counsel review on key passages.
EBB drafts with Claude; barrister reviews (~£8-15k).
Instructed via OC under client-privilege wrap; partner-level forensic.
Engaged directly (£30-50k). ICAEW standards apply either way.
Drafted with solicitor support; statement of truth.
Drafted with EBB/Claude support; barrister-reviewed.
Possible confidentiality restrictions; sensitivity around WealthVector activity as the post-removal counterfactual.
Drafted with solicitor support; statement of truth.
Drafted directly with Claude assistance; barrister-reviewed.
Confidentiality around the Grafton Fund, its investors and fund management; sensitivity around WealthVector.
Prepared by instructing firm or specialist under firm oversight.
Outsourced to bundle specialist (~£3-5k); indexed and paginated.
Solicitor-led drafting; counsel input on doctrinal points.
EBB drafts with Claude; barrister reviews tactical responses.
As CEO from 2018 through to garden leave in September 2024, Ian is the only witness with continuous, contemporaneous personal knowledge of the matters that drive the quantum argument. This is what the optimal statement would cover.
Ian's evidence is the operational anchor of the case. Before we build the case structure around it, we need to understand what's permissible by way of witness statement under any confidentiality terms.
The forensic case depends on you as the only witness with continuous CEO-level knowledge of the Plan, the pipeline and the customer relationships at the date of removal.
If confidentiality obligations narrow what you can put on record, the forensic case loses its anchor — and the Statement of Case and forensic report both have to be restructured around what's actually available.
This is a pre-Notice question, not a Phase 3 question.
Review the four corners of any settlement: confidentiality, non-disparagement, non-assistance, and any "no comment on the dispute" wording.
Take independent legal advice on what evidence is permissible within those bounds — both what would be in the optimal scope, and what would have to be excluded.
Plan the case structure around what's actually available, not the optimal scope.
If the four-corners review concludes that your statement has to be materially narrow, the forensic case structure changes — and so does the probability-weighted recovery. The dispute decision is contingent on knowing what's permissible before we serve the Notice.
An Earn-out Expert is a chartered accountant whose professional reputation depends on being defensible to both sides. The bounds of the dispute and the dynamics of the role both push the determination toward the middle.
The Expert cannot determine below Nucleus's £2.55m floor or above our ~£5m cap. Final and binding absent fraud or manifest error.
Anything below the floor is structurally out of reach. Anything at the cap requires full attribution that the Expert would have to defend.
They do not seek a reputation for strong attribution views in either direction. A determination that splits the difference is professionally defensible to both sides; one that picks an edge is not.
Even on a good case, the Expert is institutionally biased toward a middling outcome.
The Plan-vs-Actual gap is real. Some attribution to Nucleus is supportable. Full attribution would expose the Expert to criticism.
Gross upside vs Nucleus's offer: £0-£1.45m.
Floor is possible if the case is poorly presented. Cap is unlikely.
Methodology over conclusion. Range over point estimate. Engaging with the other side's case head-on. Documentary support for every assertion. Forensic independence in the report. These are the things that move the determination up within the middle — they don't get us to the cap.
An English M&A dispute of this size is conventionally staffed by an instructing law firm. We can't afford that. But running it ourselves against a top-three London firm — without representation — isn't a credible posture either.
EBB time: 100-150 hrs · Ian time: 20-40 hrs
EBB time: 250-400 hrs · Ian time: 50-100 hrs
Cash cost is roughly comparable (£100-150k vs £80-180k). The self-directed approach saves ~£20-50k of cash for 100-200 additional hours of EBB time — runs a top-three-London-firm dispute without representation, and signals our capacity to S&M from the first round of correspondence. The honest position is that neither option is genuinely viable. Both require funding we don't have.
The Sep-Oct window is the same window WealthVector needs us at maximum capacity for its critical commercial build. The conflict is direct, not theoretical.
Notice served Wed 20 May. 30-day Vendor/Purchaser meeting window. Most likely tactical settlement window.
Cost: ~£5-15k. Hours: 20-40 each.
ICC application, forensic engagement, Statement of Case drafted (60-100 hrs), witness evidence (40-60 hrs), disclosure fights (40-60 hrs).
Cost: £30-60k forensic + Expert fee share + £20-40k counsel.
Expert deliberates. S&M may surface WPSAC offer at £4.2-4.4m bracketing the likely award. Decision late Nov / early Dec. Payment 20 BDays after.
Five strengths, ten weaknesses, seven opportunities, eleven threats. Headlines only — we'll go deeper on the ones we haven't yet considered in detail on the next two slides.
Each of these is on the SWOT but easy to skim past. Read together, they're what shifts the case from "substantively strong" to "operationally not viable."
Not a letter and a phone call. 30-50 page Statement of Case, 50-80 page forensic report, witness statements, document bundle, Reply, multi-round disclosure fights. Built and lost on the documentary record.
£80-180k cash on forensic, Expert fee share, counsel, ICC application, doc bundle, contingencies. £30-60k for the forensic accountant alone is essential and cannot be deferred. The "self-service" framing understates the real cash floor.
£100-180k base, £150-400k+ if S&M force escalation. Grafton Fund can't recapitalise; other Vendors aren't contributing; personal funding is constrained by personal upside vs WV downside.
Ian's evidence is the operational anchor — without a credible witness statement, the forensic case loses its anchor. Any confidentiality terms from a settlement will narrow what he can put on record. We can't build the case structure until we know what's permissible.
The natural counterfactual for "what would have happened without Nucleus's breach" pulls WealthVector into the case theory. Ian's removal coincides with WV's formation; the impact-of-removal argument inevitably touches WV's pipeline. S&M will demand WV-related disclosure as a result.
Comms between EBB and Ian — and with the various Vendors — are not protected without instructed solicitors. Any candid email to Mike Scott (still at Nucleus) on case strategy is, in principle, discoverable. Anything strategic in those channels becomes ammunition once S&M ask for it.
A self-directed, un-funded Vendor side is visible from the first round of correspondence. The S&M playbook for that situation is well-rehearsed.
The absence of an instructed Vendor-side law firm is visible from round one. S&M's playbook for an asymmetrically-resourced counterparty: never engage on substance, always engage on procedure. Make winning unaffordable.
Their pain function is billable hours; ours is cash we don't have. The asymmetry compounds at every procedural moment.
Any case theory that leans on Ian's removal as material to the FY25 miss invites S&M to seek disclosure of EBB-Ian comms — which are predominantly WV. Once any of that is disclosed, the conflict-of-interest narrative writes itself.
This is the threat that turns a marginal commercial case into a strategically losing one.
Cl 20.4 notices crystallising the £166k retention before the 30 June 2027 long-stop. Each notice requires a substantive response. Cost of bandwidth, not necessarily of substance.
WPSAC offers calibrated to anchor at floor, timed to coincide with our submission deadlines. We either engage with the offer (distracting from the submission) or ignore it (and bear indemnity-costs risk if the Expert lands at or below the offer).
Claude transcripts with candid case-weakness, funding-constraint and WV-exposure discussion are not protected by legal advice privilege. Litigation privilege is only arguable. The transcripts are within EBB's "control" for disclosure purposes. If S&M get any of them, the dispute is effectively over.
S&M have credible mechanisms available to extend the process and increase its cost. The difference between budgeting for a 7-month process and being surprised by an 18-month one is anticipating these.
| Tactic | Estimated delay | How it works |
|---|---|---|
| Challenge to Expert jurisdiction | 3-5 months | Part 8 application in the Commercial Court arguing the Expert cannot determine the breach question. Probability ~20-30%. |
| Refusal of joint ICAEW application | 3-6 weeks | Force unilateral ICC application. Procedurally lawful but slower. |
| Engagement-letter battles | 4-8 weeks | Dispute scope, fee structure, deadlines, document protocols. |
| Disclosure obstruction | Continuous drag | Refuse § 9 information requests; force interim applications; heavy redactions. |
| Security for costs | Process-blocking | CPR 25 application against the Grafton Fund as a Jersey claimant. |
| Manifest error / fraud appeal | 3-6 months | If determination unfavourable to Nucleus, narrow-grounds appeal under Sch 3 § 1.10(b). |
£100-180k base, £150-400k+ if S&M force escalation. Six possible sources. Most are closed; the ones that aren't have real costs.
Wound-down portfolio at 0.19x residual on 3.81x already realised. Fiduciary case for asking LPs to fund the dispute doesn't present — covered on the next slide.
Off the table on the arithmetic, not for political reasons.
Tetrao: silent supporter — not financial.
Management Vendors: conflicted (Mike still employed by Nucleus).
Non-Management Vendors: supportive but not contributing.
The only remaining route from the original Vendor side. Personal recoverable upside is ~£100k each; WealthVector exposure on the downside is materially larger.
Personal funding at £100k+ is not commercially rational on that asymmetry.
30-50% of recovery + a multiple. On £1m probability-weighted gross, the funder takes £400-600k — materially eroding what's left.
Possible, but the residual return doesn't cover personal time and WV exposure.
GCL takes the early-stage spend (~£30-50k) to the Phase 3 threshold, then we reassess. Limits the initial commitment but doesn't solve the Phase 3 + escalation funding gap.
Effectively a £30-50k bet on early settlement.
Commit £50-80k personal cash with a hard stop if costs rise above that figure. Equivalent to "buy the bluff path and accept the floor if it fails."
Caps personal exposure but doesn't change the structural problem on escalation.
20-25 LPs across the Grafton Capital Delta structures — a long tail at the end of a wound-down fund. They want liquidity, not residual upside on a closed picture.
Investors are already absorbing an implicit ~15% opportunity cost on the £3.8m of admitted-but-withheld consideration while the dispute runs. Over a 9-12 month process, that's ~£430-575k of opportunity cost alone.
That wipes out a significant share of the ~£950k-£1.45m gross probability-weighted incremental upside — before legal fees, attention costs, or fund-life extension friction.
Investors at this stage of fund life are more likely to take a discount to get money back out than to want a longer hold period for a marginal lift. The Nucleus offer is already a good outcome relative to what they would accept in a secondary.
Asking them to fund a dispute is asking them to do the opposite of what their actual revealed preferences show.
Even if funding could be found, the personal-level imbalance between what EBB and Ian could each recover and what each puts at risk by pursuing is the deeper reason to walk.
Once the case theory leans on Ian's removal as material to the FY25 miss, WealthVector becomes a legitimate object of disclosure. From there, every other WV risk follows.
If our case theory says Ian's removal caused the Plan miss, S&M can fairly ask what the operational counterfactual is, and whether it extends to what Ian has built at WV since. That's a phishing expedition — but it's procedurally legitimate, and any defence undermines our own case.
Once disclosed, S&M can twist, analyse and weaponise WV's commercial activity, and take direct commercial advantage of seeing our pipeline, pricing and forecasts. WV doesn't want to spend money defending itself in someone else's dispute — and we have no budget to do it.
The UK discretionary-wealth platform market is small. Discovery of an active dispute with the incumbent IFA platform — by WV customers, prospects and advisers — is a marketing problem we cannot un-tell.
Authorisation is the critical Q3-Q4 milestone. An active commercial dispute with the incumbent introduces a fitness-and-propriety lens we don't want applied. Not a regulatory bar, but a friction multiplier on a process that already has friction.
Trying to raise the next round while WV is named in disclosure or counter-claims is materially harder. Investors read it as bridge-burning, distraction, or personality friction. The fundraise is harder for the signal even if the readings are wrong.
Once S&M have disclosure of our comms, they'll look for breaches of existing agreements (restrictive covenants, IP, employment terms) and extrapolate fact patterns to support counterclaims they can bring.
They have commercial reasons to begin new claims against WealthVector regardless of substantive merit — every claim gives them an additional handle on WV and forces us to spend bandwidth defending. The dispute itself becomes the route into WV's commercial machinery.
The dispute is a massive distraction to Ian and me right when we should be authorised and ramping up the business. We're putting WealthVector in harm's way when we don't need to. Everything we'd put at risk on the WV side is real exposure we're choosing to take on — for a £100k personal recoverable.
All three paths are on the table. Only one is defensible across all the lenses we've just walked through — substantive, fiduciary, strategic and personal.
Accept the FY25 Statement. £166k retention releases on next year's review or by the 30 June 2027 long-stop. No Notice served.
Cost: nil cash, nil attention, nil WV exposure. Fund life closes on schedule.
Why recommended: Frees the next eight months — and the strategic narrative — to compound on WealthVector.
Serve Notice and push in the § 1.7(a) window. Fold if no settlement by Day 30 and accept the floor.
Cost: ~£50k cash + 6-8 weeks. Personal-funded.
Why disfavoured: The bluff requires Nucleus to be in a hurry — they're not. Signals our capacity to S&M and absorbs early WV exposure for nothing.
Seven-month commitment. Forensic, submissions, witness statements, Reply, Expert determination, payment.
Cost: £100-180k base (£270-580k if S&M force escalation); 600-1000 combined hrs; full WV disclosure exposure.
Why disfavoured: Positive in expectation on the substantive math; every other lens argues against. Worst-case (20%) is materially negative at -£515-665k.
Bank the £3.8m. Release the £166k retention on its long-stop. Focus the next eight months on building WealthVector.